Shanghai Kehua Bio-Engineering Co.,Ltd
SHZ: 002022.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ming Li
- Employees
- 2,151
- Headquarters
- Shanghai, China
- IPO year
- 2004
- Market cap
- CN¥3.1B
- Website
- https://www.skhb.com
Loading 002022…
Loading profile data…Frequently asked questions about 002022
What does Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) do?
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and...
Where does 002022.SZ trade?
Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) trades on the Shenzhen Stock Exchange.
What sector is 002022.SZ in?
Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Shanghai Kehua Bio-Engineering Co.,Ltd?
Ming Li is the chief executive officer of Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ).
Where is Shanghai Kehua Bio-Engineering Co.,Ltd headquartered?
Shanghai Kehua Bio-Engineering Co.,Ltd is headquartered in China.
Does 002022.SZ pay a dividend?
Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 002022.SZ go public?
Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) completed its initial public offering in 2004.